Quality indicators, guidelines and outcome measures in ankylosing spondylitis

Clinical and Experimental Rheumatology

Volumn 25, Issue 6 SUPPL. 47, 2007, Pages

  Zochling, Jane ^a   Braun, Jürgen ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

Ankylosing spondylitis; ASAS core sets; Quality of care; Recommendations

Indexed keywords

ANALGESIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; EARLY DIAGNOSIS; EVIDENCE BASED PRACTICE; EXERCISE; HEALTH CARE QUALITY; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; OUTCOMES RESEARCH; PATIENT EDUCATION; PATIENT REFERRAL; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER;

HUMANS; MEDICAL RECORDS; PRACTICE GUIDELINES AS TOPIC; QUALITY INDICATORS, HEALTH CARE; REFERRAL AND CONSULTATION; REGISTRIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 36448932395     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. ZOCHLING J, VAN DER HEIJDE D, BURGOS-VARGAS R et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-52.
2. ZOCHLING J, VAN DER HEIJDE D, DOUGADOS M, BRAUN J: Current evidence for the management of ankylosing spondylitis: A systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006; 65: 423-32.
3. SIMON JA, BURGOS-VARGAS R: Agreement of Mexican rheumatologists with the Assessment in Ankylosing Spondylitis International Working Group and the European League Against Rheumatism recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 1535-6.
4. BRAUN J, ZOCHLING J, MÄRKER-HERMANN E et al.: Empfehlungen für das Management der ankylosierenden Spondylitis gemäβ ASAS/EULAR. Evaluation im deutschsprachigen Raum. Z Rheumatol 2006; 65: 728-42.
5. ZOCHLING J, VAN DER HEIJDE D, DOUGADOS M, BRAUN J: Preliminary validation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis (abstract). Int Med J 2006; 36 (Suppl. 2): A80.
6. GOSSEC L, KVIEN TK, PHILLIPS C et al.: Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: Results of a study among 1507 rheumatologists. Ann Rheum Dis 2007; 65 (n press).
7. The AGREE collaboration. Appraisa] of Guidelines for Research and Evaluation (AGREE) instrument. www.agreecollaboration.org, accessed 04 June 2007.
8. SCHACHNA L, TAYLOR A, MANOLIOS et al.: Evidence-based recommendations for the management of ankylosing spondylitis: Results of the Australian 3E initiative in rheumatology. Intern Med J 2007; 37 (Suppl. 2): A52 (abstract).
9. SIDIROPOULOS P, RAPTOPOULOU A, SIAKKA P et al.: Results of the Hellenic working group of the 3E initiative in rheumatology: Evidence-based recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2007; 65 (n press).
10. BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: A randomized controlled multi-centre trial. Lancet 2002; 359: 1187-93.
11. GORMAN JD, SACK KE, DAVIS JC: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346: 1349-56.
12. VAN DER HEIJDE D, KIVITZ A, SCHIFF MF et al. and the ATLAS STUDY GROUP: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multi-center, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46.
13. BRAUN J, DAVIS J, DOUGADOS M, SIEPER J, VAN DER LINDEN S, VAN DER HEIJDE D: First update of the International ASAS consensus statement for the use of anti-TNF-agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316-20.
14. MAKSYMOWYCH WP, INMAN RD, GLADMAN D et al.: Canadian Rheumatological Association Consensus for the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003; 30: 1356-63.
15. OLIVIERI I, SALVARANI C, CANTINI F et al.: Recommendations for starting TNF-alpha in patients with ankylosing spondylitis. Reumatismo 2003; 55: 220-3.
16. MANGER B: Revised recommendations of the Deutsche Gesellschaft fur Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases. Z Rheumatol 2002; 61: 694-7.
17. KEAT A, BARKHAM N, BHALLA A et al.: BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology 2005; 44: 939-47.
18. PHAM T, GUILLEMIN F, CLAUDEPIERRE P et al., the CLUB RHUMATISMES ET INFLAMMATION (CRI), and the SOCIETE FRANCAISE DE RHUMATOLOGIE (SFR): TNF-alpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: Recommendations of the French Society for Rheumatology. Joint Bone Spine 2006; 73: 547-53.
19. FELDTKELLER E, KHAN MA, VAN DER HEIJDE D, VAN DER LINDEN S, BRAUN J: Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23: 61-6.
20. VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
21. SIEPER J, RUDWALEIT M: Early referral recommendations for ankylosing spondylitis (including pre-radiograpbic and radiographic forms) in primary care. Ann Rheum Dis 2005; 64: 659-63.
22. BRANDT HC, SPILLER I, SONG I-H, VAHLDIEK JL, RUDWALEIT M, SIEPER J: Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis published online 24 April 2007; doi:10.1136/ard.2006.068734
23. ZOCHLING J, BRAUN J: Assessment in ankylosing spondylitis. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S133-S141.
24. VAN DER HEIJDE D, BELLAMY N, CALIN A, DOUGADOS M, KHAN MA, VAN DER LINDEN S: Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997; 24: 2225-9.
25. VAN DER HEIJDE D, VAN DER LINDEN S, DOUGADOS M, BELLAMY N, RUSSELL AS, EDMONDS J: Ankylosing spondylitis: Plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol 1999; 26: 1003-5.
26. WORLD HEALTH ORGANISATION (WHO): International Classification of Functioning, Disability and Health: ICF. Geneva, WHO; 2001.
27. VAN ECHTELD I, CIEZA A, BOONEN A et al.: Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol 2006; 33: 2475-83.
28. SIGL T, CIEZA A, VAN DER HEIJDE D, STUCKI G: ICE based comparison of disease specific instruments measuring physical functional ability in ankylosing spondylitis. Ann Rheum Dis 2005; 64: 1576-81.
29. MACLEAN CH: Quality indicators for the management of osteoarthritis in vulnerable elders. Ann Int Med 2001; 135 (8 Part 2): 711-21.
30. KHANNA D, ARNOLD E, PENCHARZ JN et al.: Measuring process of arthritis care: The Arthritis Foundation's Quality Indicator Set for Rheumatoid Arthritis. Semin Arthritis Rheum 2006; 35: 211-37.
31. MIKULS T, MACLEAN CH, OLIVIERI J et al.: Quality of care indicators for gout management. Arthritis Rheum 2004; 50: 937-43.
32. SAAG KG, OLIVIERI JJ, PATINO F, MIKULS TR, ALLISON JJ, MACLEAN CH: The Arthritis Foundation's quality indicators for nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesic therapies. Arthritis Rheum 2004; 51: 337-49.